Question explored with the scientific record
Did research in to treatment of Down syndrome decrease after prenatal screening and selective abortion in public health became routine?
The short version: the retrieved evidence cannot answer this. It contains no study of research funding or output on Down syndrome treatments over time.
The records that touch Down syndrome are clinical, not bibliometric. One is a 1981 case report on aborting one twin with Down syndrome while the other was delivered healthy [13]. Another is a 1997 survey of Chinese genetic providers, in which 94% would support termination for Trisomy 21 in the first trimester [10]. Neither measures research activity, funding, or publication counts. The rest of the retrieval is off-topic: childhood cancer wait times [1], heart drugs [2], leukemia [3], fragile X [4], facial palsy [5], liver cancer [6], metabolic syndrome [7][8], toxoplasmosis screening [9], folic acid [11], and thalassemia in twins [12].
So the honest answer is that this search surfaced nothing that tests your hypothesis. Answering it properly needs a different kind of evidence entirely: publication and grant databases (PubMed counts, NIH RePORTER, clinicaltrials.gov) tracking Down syndrome treatment trials before and after routine prenatal screening became standard. That is a bibliometric question, and no clinical trial answers it.
What I can say from reasoning, clearly labeled as outside these records: a decline in the number of affected births would shrink the commercial market for any treatment, and market size shapes industry research investment. That is a plausible mechanism, not a finding. Whether it actually happened is unknown to me and unaddressed by anything retrieved here.
My call: the evidence retrieved does not answer whether Down syndrome treatment research declined after routine screening and abortion, and I will not pretend a case report and an attitudes survey settle it. Confidence: not clear.
Sources used 13
-
Waiting times for cancer care in Canadian children: Impact of distance, clinical, and demographic factors
Distance from residence to treating pediatric oncology center did not significantly affect waiting times for diagnostic and treatment events in Canadian children with cancer after adjustment.
DOI: 10.1002/pbc.20156 -
Targeting inflammation—what has the VISTA-16 trial taught us?
The VISTA-16 trial investigated the effects of the secretory phospholipase A2 inhibitor varespladib on cardiovascular events in patients with acute coronary syndrome, ultimately leading to the trial's termination due to futility and potential harm despite initial enthusiasm for …
DOI: 10.1038/nrcardio.2013.220 -
Selective liver toxicity and therapeutic progress in acute lymphoblastic leukaemia
This Lancet Haematolgy commentary discusses the INO-VATE phase 3 trial in adults with relapsed/refractory CD22-positive B-lineage ALL, highlighting higher sinusoidal obstruction syndrome risk with inotuzumab ozogamicin but improved survival when followed by HSCT, and outlining r…
DOI: 10.1016/S2352-3026(17)30121-7 -
Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome
This study validates a six-factor Aberrant Behavior Checklist-Community (ABC-C) structure for Fragile X syndrome, investigates how anxiety and ADHD relate to ABC-C problem behaviors, and assesses how these factors predict caregiver burden, finding that irritability most strongly…
DOI: 10.1002/AJMG.A.36232 -
Acute “idiopathic” peripheral facial palsy: Clinical, serological, and cerebrospinal fluid findings and effects of corticosteroids
A prospective study of 147 patients with acute peripheral facial palsy of unknown origin identifying etiologies (Borrelia burgdorferi, herpesviruses including EBV, and other viral infections) via CSF and serology, finding no significant benefit of corticosteroids overall and not…
DOI: 10.1016/0196-0709(93)90027-5 -
Hepatocellular carcinoma in non-alcohol fatty liver disease – changing trends and specific challenges
This narrative review synthesizes current evidence on hepatocellular carcinoma arising in nonalcoholic fatty liver disease (NAFLD/NASH), detailing epidemiologic trends, risk factors (obesity, diabetes, fibrosis), differences from viral etiologies, diagnostic/screening challenges…
DOI: 10.1080/03007995.2019.1683817 -
The Impact of Cardiovascular Risk Factor Case Management on the Metabolic Syndrome in a Primary Prevention Population: Results From a Randomized Controlled Trial
A 6-month nurse-based cardiovascular case management program modestly reduced the prevalence of the metabolic syndrome at 1 year in a primary prevention cohort.
DOI: 10.1111/j.0197-3118.2006.0.x -
Coronary Artery Calcium Screening in Persons with Metabolic Syndrome and Diabetes: Implications for Prevention
This narrative review argues that coronary artery calcium screening improves CHD risk stratification in asymptomatic persons with metabolic syndrome or diabetes, though no trial shows it improves clinical outcomes.
DOI: 10.1089/met.2012.0165 -
Diagnosing maternofetal toxoplasmosis.
Collection of BMJ Letters (1991) containing brief clinical and public health commentaries on topics including legal automatism, ocular prostheses, maternofetal toxoplasmosis screening, and physiotherapy for stress incontinence, rather than reporting a single cohesive study.
DOI: 10.1136/bmj.302.6786.1208-b -
China's genetic services providers' attitudes towards several ethical issues: a cross‐cultural survey
A national cross-cultural survey of 255 Chinese genetic services providers (out of 402 invited) across 30 provinces assessing attitudes toward ethical, legal and social issues in genetics—such as abortion, sex selection, genetic counseling, disclosure of genetic information, and…
DOI: 10.1111/j.1399-0004.1997.tb02526.x -
Primary prevention of neural tube defects with folic acid supplementation: Cuban experience
In a Cuban series, 5 mg daily periconceptional folic acid was followed by no NTD recurrences among 81 fully supplemented women versus four (3.5%) among 114 unsupplemented women, a difference the authors report as not statistically significant.
DOI: 10.1002/pd.1970100303 -
Prenatal diagnosis of thalassemia in twin pregnancies in mainland China
This study reports on the prenatal diagnosis of thalassemia in twin pregnancies at a tertiary referral center in mainland China, highlighting the challenges and outcomes associated with managing such cases over an eight-year period.
DOI: 10.3109/01443615.2016.1148678 -
Twin pregnancy, abortion of one fetus with Down's syndrome by sectio parva, the other delivered mature and healthy
This case report describes a successful surgical intervention to abort a fetus with Down's syndrome in a twin pregnancy, allowing the unaffected twin to be delivered healthy at term.
DOI: 10.1016/0028-2243(81)90048-4